A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG-012 Injections in Patients with Alport Syndrome
Sponsor: |
Regulus Therapeutics |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ9729 |
U.S. Govt. ID: |
NCT02855268 |
Contact: |
Michael Toledo: 212-305-6842 / mt3013@columbia.edu |
Alport syndrome is a condition people are born with. It causes damage to the kidneys over time. The purpose of this research study is to evaluate the safety and effectiveness (how well it works) of RG-012 compared to placebo (an inactive substance that contains no medicine) as a treatment for patients with Alport syndrome. We will also look at how the body absorbs and breaks down RG-012 and how RG-012affects the body.Sponsor delayed initiation: 6/13/2017
This study is closed
Investigator
Gerald Appel, MD
Have you been diagnosed with Alport Syndrome? |
Yes |
No |